A recent study indicates that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Published data in a prominent health publication shows that while overweight people frequently drop substantial amounts of their total mass while using the jabs, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Users buying these treatments need to be aware of the risk of quick rebound weight gain when the therapy concludes," warns expert Dr. Susan Jebb.
That rate of recovery implies a return to original weight in about 18 months.
Analyzing Therapies
The research, which examined 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.
Scientists point out that individuals who shed pounds through diet and exercise typically have a slower weight regain—perhaps 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts believe the mechanism of the injections explains the amplified weight return.
These medications imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication results in hunger is uncontrolled, making excessive eating much more probable."
A Chronic Issue?
Medical guidelines suggest the injections for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, due to the likelihood of relapse, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who say that the findings "underscore the persistent character of obesity," comparing it to managing diseases like diabetes.
User Experiences
People who have stopped the jabs report a intense return of hunger.
"I experienced something activating and you become starving," described one woman.
This challenge is worsened if users have not adopted permanent lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates show that millions of adults in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, experts emphasize that while the jabs are effective agents for shedding pounds, they are not a permanent fix and maintained weight loss hinges on ongoing behavioural changes.
